Cargando…

BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma

The expression of the BCL-2 family proteins, BCL-2, BAX, BCL(XL)and BAK have been determined in a panel of 12 human ovarian carcinoma cell lines encompassing a wide range in sensitivity to cisplatin. Whereas BAX, BCL(XL)and BAK levels did not correlate with sensitivity, there was a statistically sig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beale, P J, Rogers, P, Boxall, F, Sharp, S Y, Kelland, L R
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2000
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363292/ https://www.ncbi.nlm.nih.gov/pubmed/10646901 http://dx.doi.org/10.1054/bjoc.1999.0939

Ejemplares similares

Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines.
por: Sharp, S. Y., et al.
Publicado: (1998)

Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts.
por: Jones, M., et al.
Publicado: (1993)

Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin
por: O’Neill, C F, et al.
Publicado: (1999)

The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.
por: Mistry, P., et al.
Publicado: (1991)

Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes.
por: Loh, S. Y., et al.
Publicado: (1992)

In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473.
por: Holford, J., et al.
Publicado: (1998)

Reversing platinum resistance in ovarian cancer multicellular spheroids by targeting Bcl-2
por: Yang, Ya’nan, et al.
Publicado: (2019)

Characterization and modulation of drug resistance of human paediatric rhabdomyosarcoma cell lines
por: Cocker, H A, et al.
Publicado: (2000)

In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
por: Mellish, K. J., et al.
Publicado: (1993)

Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines.
por: Sharp, S. Y., et al.
Publicado: (1994)

Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes.
por: Hills, C. A., et al.
Publicado: (1989)

Bcl-w expression in colorectal adenocarcinoma
por: Wilson, J W, et al.
Publicado: (2000)

Depletion of protein kinase C (PKC) by 12- O -tetradecanoylphorbol-13-acetate (TPA) enhances platinum drug sensitivity in human ovarian carcinoma cells
por: Isonishi, S, et al.
Publicado: (2000)

Bcl-2 expression related to altered p53 protein and its impact on the progression of human pancreatic carcinoma
por: Hu, Y-X, et al.
Publicado: (1999)

Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.
por: McKeage, M. J., et al.
Publicado: (1994)

Prognostic significance of bcl-2 expression in leiomyosarcoma of the uterus
por: Zhai, Y-L, et al.
Publicado: (1999)

Bcl10 is not a target for frequent mutation in human carcinomas
por: Lambers, A R, et al.
Publicado: (1999)

Surgery in platinum-resistant recurrent epithelial ovarian carcinoma
por: Zhao, Ling-Qin, et al.
Publicado: (2022)

Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas
por: Affatato, Roberta, et al.
Publicado: (2022)

Establishment and Characterization of Acquired Resistance to Platinum Anticancer Drugs in Human Ovarian Carcinoma Cells
por: Misawa, Toshiya, et al.
Publicado: (1995)

Multi-Gene Expression Predictors of Single Drug Responses to Adjuvant Chemotherapy in Ovarian Carcinoma: Predicting Platinum Resistance
por: Ferriss, J. Stuart, et al.
Publicado: (2012)

Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer
por: Borner, M M, et al.
Publicado: (1999)

Impaired FHIT expression characterizes serous ovarian carcinoma
por: Ozaki, K, et al.
Publicado: (2001)

Nucleolar damage correlates with neurotoxicity induced by different platinum drugs
por: McKeage, M J, et al.
Publicado: (2001)

Overcoming the challenges of drug development in platinum-resistant ovarian cancer
por: Eskander, Ramez N., et al.
Publicado: (2023)

Low expression of bcl-2 in Brca1-associated breast cancers
por: Freneaux, P, et al.
Publicado: (2000)

Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2
por: Schuyer, M, et al.
Publicado: (2001)

Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen
por: Kupryjańczyk, J, et al.
Publicado: (2003)

Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs
por: Screnci, D, et al.
Publicado: (2000)

Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells
por: Roberts, D, et al.
Publicado: (2005)

Met/HGF receptor modulates bcl-w expression and inhibits apoptosis in human colorectal cancers
por: Kitamura, S, et al.
Publicado: (2000)

Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels.
por: Raynaud, F. I., et al.
Publicado: (1996)

Paradoxical regulation of Bcl-2 family proteins by 17β-oestradiol in human breast cancer cells MCF-7
por: Leung, L K, et al.
Publicado: (1999)

Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma
por: Shen, G H, et al.
Publicado: (2000)

Proteomic and Bioinformatic Studies for the Characterization of Response to Pemetrexed in Platinum Drug Resistant Ovarian Cancer
por: Severi, Leda, et al.
Publicado: (2018)

Presence of activin signal transduction in normal ovarian cells and epithelial ovarian carcinoma
por: Ito, I, et al.
Publicado: (2000)

Decitabine reactivated pathways in platinum resistant ovarian cancer
por: Fang, Fang, et al.
Publicado: (2014)

Repurposing Drugs in Controlling Recurrent Platinum-Resistant Clear-Cell Ovarian Cancer
por: Sinsuwan, Woraporn, et al.
Publicado: (2023)

Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma
por: Ito, Y, et al.
Publicado: (2001)

Nuclear Expression of Pygo2 Correlates with Poorly Differentiated State Involving c-Myc, PCNA and Bcl9 in Myanmar Hepatocellular Carcinoma
por: Htun, Myo Win, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a3kv4roesanus366bfkvnku31v